XENE - Xenon Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.10
-0.45 (-4.27%)
At close: 4:00PM EDT

10.60 +0.50 (4.95%)
After hours: 6:15PM EDT

Stock chart is not supported by your current browser
Previous Close10.55
Open10.65
Bid9.90 x 3100
Ask10.85 x 1200
Day's Range9.90 - 10.75
52 Week Range2.10 - 11.00
Volume108,502
Avg. Volume267,339
Market Cap178.349M
Beta0.42
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateAug 1, 2018 - Aug 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.33
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Xenon Pharmaceuticals Announces At-The-Market Equity Offering

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, announced today that it has entered into an at-the-market equity offering sales agreement with Jefferies and Stifel, effective as of July 11, 2018, under which Xenon may sell its common shares, from time to time, for up to $50.0 million in aggregate sales proceeds in "at the market" transactions. In connection with Xenon’s entry into the at-the-market equity offering sales agreement, its prior at-the-market equity offering sales agreement that it entered into with Stifel on May 8, 2018 was mutually terminated by Xenon and Stifel effective as of July 11, 2018.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of XENE earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Xenon Pharmaceuticals Inc Earnings Call

  • GlobeNewswirelast month

    Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

    BURNABY, British Columbia, June 01, 2018-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present ...

  • ACCESSWIRE2 months ago

    Blog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat Conference

    LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Xenon Pharma Inc. (NASDAQ: XENE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=XENE as the Company's latest news hit the wire. On May 15, 2018, the Company announced that it has presented positive interim data from its ongoing XEN1101 Phase-1 clinical trial in a podium presentation at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (Eilat) held in Madrid, Spain. Active-Investors.com is currently working on the research report for Coherus BioSciences, Inc. (NASDAQ: CHRS), which also belongs to the Healthcare sector as the Company Xenon Pharma.

  • GlobeNewswire2 months ago

    Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today presented positive interim data from its ongoing XEN1101 Phase 1 clinical trial in a podium presentation at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (Eilat) held in Madrid, Spain. Today, Xenon presented interim data from its ongoing XEN1101 Phase 1 clinical trial, which is evaluating the safety, tolerability and pharmacokinetics of both single ascending doses (SAD) and multiple ascending doses (MAD) of XEN1101 in healthy subjects, along with results from the completed Phase 1a pilot transcranial magnetic stimulation (TMS) study in 8 healthy subjects.

  • GlobeNewswire2 months ago

    Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today presented new pre-clinical data as well as preliminary clinical data from its ongoing XEN901 Phase 1 clinical trial in a podium presentation at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (Eilat) held in Madrid, Spain. XEN901 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed by Xenon for the treatment of epilepsy including treatment resistant adult and pediatric focal seizures, as well as rare, pediatric forms of epilepsy, such as EIEE13, an early infantile epileptic encephalopathy due to gain-of-function mutations in the SCN8A gene that encodes the Nav1.6 sodium channel.

  • GlobeNewswire2 months ago

    Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference

    BURNABY, British Columbia, May 14, 2018-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that it will provide a corporate update and overview of the presentations ...

  • Benzinga2 months ago

    The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space. Here's a compilation of key biotech ...

  • Associated Press2 months ago

    Xenon Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 21 cents. Xenon Pharmaceuticals shares have more than doubled since the beginning of the year. In the final minutes ...

  • GlobeNewswire2 months ago

    Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

    Xenon’ s novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming 14th Eilat Conference on New Antiepileptic Drugs and Devices on May 15, 2018. BURNABY, British Columbia, ...

  • GlobeNewswire2 months ago

    Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate Update

    BURNABY, British Columbia, May 01, 2018-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results ...

  • GlobeNewswire3 months ago

    Xenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference

    BURNABY, British Columbia, April 25, 2018-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present ...

  • Teva Terminates TV-45070 Development Agreement with Xenon
    Market Realist4 months ago

    Teva Terminates TV-45070 Development Agreement with Xenon

    On March 7, 2018, Teva Pharmaceutical (TEVA) with Teva Canada and Xenon Pharmaceuticals (XENE) entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012 for the pain drug TV-45070. During Xenon Pharmaceuticals’ 2017 earnings results release, it announced the agreement termination news. On the day, TEVA stock rose ~0.8%, while Xenon stock rose ~7%. Teva Pharmaceutical stated that it was no longer interested in the development of TV-45070.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of XENE earnings conference call or presentation 7-Mar-18 9:30pm GMT

    Q4 2017 Xenon Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE4 months ago

    Xenon Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern ...

  • Benzinga4 months ago

    Xenon Pharmaceuticals Q4 Earnings Outlook

    Xenon Pharmaceuticals (NASDAQ: XENE ) unveils its next round of earnings Wednesday. Get prepared with Benzinga's ultimate preview for Xenon Pharmaceuticals' Q4 earnings. Earnings and Revenue Analysts covering ...

  • Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube8 months ago

    Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Xenon Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Xenon Pharmaceuticals, Inc. – Chimerix, Inc. (CMRX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.26 million, Net Earnings of USD -7.74 million. ... Read more (Read more...)